Market Overview:

The global tumor ablation market reached a value of US$ 920 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,900 Million by 2027, exhibiting a CAGR of 12.7% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Tumor ablation refers to a minimally invasive (MI) technique that is conducted to treat tumors of the kidney, liver, bones and lungs. The ablation system consists of a generator and a needlelike device that delivers the heat directly to the target cells to cause acute cellular necrosis. The procedure destroys benign tumors by inserting a probe and heating it to 100-degree Celsius under Precise Computer Tomography, without extracting them from the body. It can be conducted through Microwave Ablation, Radiofrequency Ablation, Cryoablation, etc. It provides increased accuracy and covers a larger treatment area, along with minimal pain and risk to the patient upon repeated administrations.

The increasing prevalence of cancer is one of the key factors driving the growth of the market. Furthermore, owing to benefits such as the lesser amount of trauma, speedy recovery, reduced complications and shorter hospital stay, MI procedures are gaining widespread preference, which, in turn, is driving the market growth. Also, various technological advancements such as the introduction of thermal and laser ablation, irreversible electroporation and High-Intensity Focused Ultrasound (HIFU) have enhanced the acceptance of tumor ablation procedures. Moreover, the implementation of favorable government policies for cancer awareness and treatment methods is also creating a positive outlook for the market. Other factors driving the market include growing healthcare expenditures and rising geriatric population, along with the increasing number of ablation and surgical centers and awareness for ablation procedures that can be conducted over small tumors.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global tumor ablation market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on technology, mode of treatment, mode of application and end-user.

Breakup by Technology:

• Radiofrequency (RF) Ablation
• Microwave Ablation
• Cryoablation
• Others
   

Breakup by Mode of Treatment:

• Percutaneous Ablation
• Laparoscopic Ablation
• Surgical Ablation
   

Breakup by Mode of Application:

• Liver Cancer
• Lung Cancer
• Kidney Cancer
• Bone Metastasis
• Others
   

Breakup by End-User:

• Hospitals
• Cancer Specialty Clinics
• Others
   

Breakup by Region:

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America
   

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Medtronic Public Limited Company, AngioDynamics, Inc., HealthTronics, Inc., NeuWave Medical, Inc., INTIO, Inc., Galil Medical Ltd., Boston Scientific Corporation, SonaCare Medical, LLC, EDAP TMS S.A., Erbe Elektromedizin GmbH, IceCure Medical Ltd., MISONIX Inc., Endocare Inc., CooperSurgical Inc. and B V M Meditech Pvt.

Report Coverage: